Fig. 5: Effects of miR-132-5p knockdown on depression-like phenotype in CRS-induced mice.

A Treatment schedule. Chronic restraint stress (CRS) was performed 7 days (day 1–day 7). Subsequently, antagomiR-132-5p (200 nmol, 2 μl/day) or antagomiR-NC (control: 2 μl/day) was administered i.c.v. to mice 3 days after CRS (day 8–day 10). Locomotion test, forced swimming test (FST) and sucrose preference test (SPT) were performed after the injection of antagomiR-NC or antagomiR-132-5p (day 11 and day 12). The prefrontal cortex (PFC) was collected after SPT. B Body weight change (two-way repeated measures ANOVA: F4,52 = 1,125, P = 0.300). C Locomotion test (one-way ANOVA: F2,26 = 0.587, P = 0.563). D FST (one-way ANOVA: F2,26 = 6.709, P = 0.005). E SPT (one-way ANOVA: F2,26 = 5.581, P = 0.010). F Expression of miR-132-5p in the PFC (one-way ANOVA: F2,26 = 10.470, P = 0.0005). G Bdnf mRNA in the PFC (one-way ANOVA: F2,26 = 15.740, P < 0.0001). The data represent mean ± SEM (n = 9 or 10). *P < 0.05, **P < 0.01, ***P < 0.001. N.S., not significant.